Seismic Therapeutic

Seismic applies machine learning to immunology drug discovery, drawing on a team experienced in biologics discovery and development.

Seismic Therapeutic is building a pipeline of biologics from its IMPACT platform to address dysregulated adaptive immunity.

The page describes how interactions among T cells and B cells/antigen-presenting cells contribute to many autoimmune diseases.

Timothy A. Springer, PhD, is a Lasker Award honoree, Seismic founder, and professor at Harvard Medical School and Boston Children’s Hospital.

Seismic Therapeutic appointed Eric Larson and Heather Vital to leadership roles; the announcement notes their financial and strategic planning experience across product development and company growth.

Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, appointed Maude Tessier, PhD, as chief business officer. Tessier has over 16 years of company-building experience.

Timothy A. Springer, PhD, a founding investor and academic co-founder of Seismic Therapeutic, was selected as a co-recipient of the 2022 Albert Lasker Basic Medical Research Award.

Seismic Therapeutic announced multiple drug programs targeting adaptive immunity to treat autoimmune diseases and described its IMPACT platform’s role in biologics discovery and optimization.

Seismic Therapeutic describes its process as open and collaborative and says it focuses on rigorous science and patient impact.

Seismic Therapeutic 250 Arsenal Place, Suite 210 Watertown, MA 02472 617-294-9424 info@seismictx.com

Seismic Therapeutic is a clinical-stage immunology company creating transformative biologic medicines for autoimmune and inflammatory diseases.

Seismic Therapeutic’s privacy policy covers personal information processed in its business and collected through its website and related online or offline services.